Pioneering Innovation, Sailing Global: 2025 Dongyao Pharma Private Board Meeting Successfully Concludes

Li Yuan, Founder and CEO of BioPlusIn the opening remarks, it was pointed out that a new generation of antibody drugs, represented by bispecific antibodies and antibody-drug conjugates (ADCs), is driving industry transformation. It has become an inevitable trend for Chinese biotech companies to expand globally through licensing collaborations, mergers and acquisitions, and other models. Global expansion is not a solitary voyage, but rather a strategy of collaborative engagement.

Dr. Liu Jun, CEO and Executive Director of Tot BiopharmHe delivered the opening welcome address, stating that China’s biopharmaceutical industry has entered a new “technology-driven” phase of global expansion. Local innovations are gaining international recognition, and license-out deals are experiencing explosive growth, as China accelerates its transition from a “participant” to a “contributor” in the global pharmaceutical landscape. He called on innovative enterprises, CDMOs, investment institutions, and international partners to work closely together to build a globally competitive “Chinese global expansion supply chain,” achieving mutual benefits for all stakeholders.

Liu Jun, CEO and Executive Director of Tot Biopharm

Global Clinical Frontiers Update

Exploring Opportunities and Challenges Amid the Upgrade of Globalization Strategies

This private advisory board meeting focuses on the global frontier of oncology treatment and the international development of innovative Chinese pharmaceuticals.Professor Gong Jifang, Deputy Director of the Phase I Clinical Ward, Peking University Cancer HospitalASCO Recap: Notable Clinical Advances in Gastrointestinal Cancers Reveal New Global Benchmarks for Solid Tumor Therapy. China’s advantages in clinical capabilities, policy support, and R&D efficiency are accelerating the resolution of unmet clinical needs and driving broader international recognition of domestic innovations.

Gong Jifang, Deputy Director of the Phase I Clinical Ward, Peking University Cancer Hospital

Within the framework of exploring the upgrading of global ecological strategies and the overseas expansion opportunities for biotech companies,Dr. Xie Zhiyi, Vice President of Global Clinical R&D, Asia-Pacific Region, BioNTechDelivered insights with an international perspective, sharing strategies for the pipeline layout and clinical development of bispecific antibodies/ADCs.

Xie Zhiyi, Vice President of Global Clinical R&D, Asia-Pacific, BioNTech

Tot Biopharm Expands Overseas Together

Fifteen Years of Accumulation Forge the Cornerstone of Globalization

Dr. Liu Jun, CEO and Executive Director of Tot Biopharm, shared the “Going Global Together” strategy. He emphasized that addressing global health challenges requires strengthened innovation and connectivity, and that the key to the successful international expansion of Chinese pharmaceutical companies lies in industrial synergy, jointly shaping overall competitiveness with Chinese enterprises as the main body.

Dr. Liu shared the solid foundation underpinning the company’s transition into an international CDMO, built upon fifteen years of accumulation: a globally recognized quality system, large-scale commercial manufacturing capabilities, and differentiated advantages. He also introduced Tot Biopharm’s core empowerment model: adhering to customers’ key demands for quality, speed, and cost, and leveraging an integrated technology platform and extensive experience to achieve “single-site” global delivery, thereby helping clients rapidly expand into overseas markets amid intense global competition.

“Ecological synergy” is the strategic core, aiming to unite multiple partners to build global competitiveness and promote the overseas expansion of “Chinese technology + services.” The company also announced that it will officially launch its new English brand, “BioDlink,” in 2025, marking a strategic and cultural upgrade. This move conveys its professional strengths in the field of large molecules such as monoclonal antibodies, bispecific antibodies, ADCs, and XDCs, as well as its philosophy of relying on innovation, adhering to compliance and quality, linking the industry, and jointly building an ecosystem.

The Meaning of Tot Biopharm's New Logo

Peak Debate

Monoclonal Antibodies/Bispecific Antibodies/Polyclonal Antibodies vs. ADCs

Clinical Development and BD Strategy

“How to Persuade Global PIs to Lead Clinical Trials? How to Secure Billion-Dollar Partnerships with MNCs?” Industry Leaders Engage in Fierce Debate on These Two Key Questions.

Bao Jun, CBO of Promab Biotechnologies, joined forces with Xia Zhinan, Founder and CSO of Abimmune Bio, and Deng Lingquan, Partner at Mifang Health Fund, to form the Antibody Team. Xia Mingde, Co-founder and CEO of InnoLake Pharmaceuticals, teamed up with Xiao Liang, CEO of i-lncubator Medical Innovation Incubator, and Fan Yichao, Investment Director at the CICC-AstraZeneca Healthcare Industry Fund, to form the ADC Team. The two sides exchanged frequent insights and engaged in fierce debate, bringing the event to a climax.

Antibody CampandADC Sectorpresented their respective viewpoints, and the atmosphere at the venue was lively,Xie Ting, Managing Director of Hillhouse VenturesDelivering the final summary, he emphasized the importance of adopting a long-term investment horizon and exercising patient capital, urging everyone to pursue what they believe is right and to persevere. At the conclusion of the debate, an on-site vote was conducted,Mou Yiping, General Manager of Nanomicro TechandZhu Xiangying, Founder and CEO of Hengyu BioAward Presentation to the Best Debater.

Traditional antibody therapies and ADCs each have their own strengths, and looking at the development of the industry as a whole,Antibody-ADC Conjugation: A Key Direction for Addressing Unmet Clinical Needs in the Future, it offers patients more effective treatment options through a precise delivery mechanism.

Best Debater of the Antibody Team

Bao Jun, CBO of Premabio

Best Debater of the ADC Team

Fan Yichao, Investment Director of the AstraZeneca CICC Healthcare Industry Fund

Mou Yiping, General Manager of Nanowave Technologystated, “We have an excellent collaboration with Tot Biopharm. In particular, Mr. Liu Jun also highlighted our customers’ focus on speed, quality, and cost. We are honored to have been recognized as the Best Supplier in the first year of our partnership with Tot Biopharm and as the Best Partner in 2024.”

Dr. Zhu Xiangying, Founder and CEO of Hengyu BiotechUpon announcing the ADC Award at the debate competition, he stated, “I am delighted to share this moment with Tot Biopharm, our long-standing partner since its inception, and I sincerely hope that together we can truly propel China’s ecosystem onto the global stage.”

Closed-Door Seminar

Full-Chain Strategy for Tackling Challenges in Global Expansion

Strategic Considerations and Experience Behind BD Transactions

All attendees focused on in-depth discussions of the core aspects of Biotech’s global expansion, centering on “Key Stages in Biotech’s Global Expansion: Project Initiation, Clinical Development, Quality, and CMC.” Through sharing practical experiences in BD-licensing-driven internationalization, they explored the strategies behind BD transactions.

Amidst a vibrant exchange of ideas and heated discussions, the following core consensus was reached on-site:

After years of capital infusion, Chinese biotech has evolved from “global obscurity” to “global visibility”—full-chain capabilities are reshaping the innovative drug landscape.

Finally, as a partner,Xie Hongyan, Vice President of Cobetter“The partnership between Cobetter and Tot Biopharm goes beyond mere product supply, having deepened into joint R&D (e.g., Tot Biopharm has applied Cobetter’s membrane chromatography products in ADC purification processes and filed for patents). We look forward to more innovative synergies in the future to jointly drive industry progress.”

This private advisory board meeting is not only a platform for the exchange of ideas, but also marks the Chinese biopharmaceutical industry“From Going It Alone to Advancing Side by Side”Strategic Upgrade.

The Core of Successful Global Expansion for China’s Innovative Drugs Lies in Strengthening the Foundation of Capabilities,Rigorous Quality System and CMC ComplianceIt is the lifeline and fundamental requirement for enterprises entering the international market. BioDlink is committed to leveraging its strength within the ecological synergy circle, relying on CMC technology and a one-stop commercialization service platform to empower Biotech companies in efficient R&D, accelerate the drug launch process, facilitate the global accessibility of China’s original research achievements for patients worldwide, and contribute Chinese strength to human health.

In the future, Tot Biopharm willBioDlink: A New Starting Point, we will continue to open up our international capability pool, joining hands with the industry to embark on a new era of global expansion—“Leading Drug Innovation, Going Global Together.”"Let Chinese Solutions Become Global Answers."

* Disclaimer:The expert opinions presented herein are derived from the sharing and discussions at the private advisory board meeting, reflecting the outcomes of the exchanges during the conference. While every effort has been made to faithfully record these views, they have not undergone independent post-hoc review by the speakers.